What is the price target for PRVB stock?
12 analysts have analysed PRVB and the average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98.
PROVENTION BIO INC (PRVB) Forecast, Price Target & Analyst Ratings
NASDAQ:PRVB • US74374N1028
Current stock price
24.98 USD
+0.75 (+3.1%)
At close:
25 USD
+0.02 (+0.08%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROVENTION BIO INC (PRVB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 2, 2023
- Period
- Q1 / 2023
- EPS Estimate
- -$0.88
- Revenue Estimate
- 3.57M
Price Target Details & History
Consensus Price Target and Range
Mean target
$24.48
Upside
-2.00%
From current price of $24.98 to mean target of $24.48, Based on 12 analyst forecasts
Low
$19.19
Median
$25.50
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
21.74%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for PRVB. The average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98.
The average price target has been revised upward by 21.74% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.33%
PRVB was analyzed by 12 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about PRVB.
In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
PRVB was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-03-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-03-14 | SMBC Nikko | Downgrade | Outperform -> Neutral |
| 2023-03-14 | Jefferies | Downgrade | Buy -> Hold |
| 2023-03-13 | Chardan Capital | Maintains | Buy |
| 2023-02-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-21 | Chardan Capital | Maintains | Buy |
| 2022-11-21 | SVB Leerink | Maintains | Outperform |
| 2022-11-18 | Oppenheimer | Maintains | Outperform |
| 2022-11-18 | Jefferies | Maintains | Buy |
| 2022-11-04 | Chardan Capital | Maintains | Buy |
| 2022-10-07 | Jefferies | Maintains | Buy |
| 2022-09-20 | Jefferies | Initiate | Buy |
| 2022-08-05 | Chardan Capital | Maintains | Buy |
| 2022-07-11 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-06 | Oppenheimer | Maintains | Outperform |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-13 | Chardan Capital | Maintains | Buy |
| 2021-04-12 | HC Wainwright & Co. | Reiterate | Buy |
| 2021-04-09 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-04-09 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2021-04-09 | SVB Leerink | Maintains | Outperform |
| 2021-02-22 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 2, 2023
- Period
- Q1 / 2023
- EPS Estimate
- -$0.88
- Revenue Estimate
- 3.57M
- Revenue Q2Q
- 515.52%
- EPS Q2Q
- -152.57%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
-39.66%
Revenue (3 Months)
-12.50%
EPS (1 Month)
-79.31%
EPS (3 Months)
-54.76%
Next Earnings Summary
PRVB is expected to report earnings on 8/2/2023. The consensus EPS estimate for the next earnings is -0.88 USD and the consensus revenue estimate is 3.57M USD.
The next earnings revenue estimate has been revised downward by 12.5% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.395M | 12.895M 824.37% | 44.718M 246.79% | 133.08M 197.60% | 416.71M 213.13% | 504.9M 21.16% | 733.38M 45.25% | 958.8M 30.74% | 1.119B 16.71% | 1.23B 9.92% | ||
| EBITDA YoY % growth | -99.66M | -115.191M -15.58% | -126.933M -10.19% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -99.69M -124.68% | -115.578M -15.94% | -128.161M -10.89% | -159.876M -24.75% | -70.645M 55.81% | 67.069M 194.94% | 126.33M 88.36% | 516.07M 308.51% | 686.15M 32.96% | 767.5M 11.86% | 848.69M 10.58% | |
| Operating Margin | N/A | -8,285.16% | -993.88% | -357.52% | -53.08% | 16.09% | 25.02% | 70.37% | 71.56% | 68.59% | 69.00% | |
| EPS YoY % growth | -1.85 -72.90% | -1.82 1.62% | -1.60 12.09% | -1.90 -18.96% | -0.61 67.71% | 0.87 241.08% | 0.81 -7.06% | 5.62 597.47% | 7.20 28.13% | 8.05 11.76% | 8.89 10.52% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.88 -152.57% | -0.77 -67.04% | -0.51 -50.00% | -0.33 27.47% |
| Revenue Q2Q % growth | 3.57M 515.52% | 6.63M 788.74% | 9.69M 1,181.75% | 15.674M 44.96% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -75.072M -158.15% | -42.687M -43.09% | -40.698M -39.96% | -26.112M 34.99% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
36.47%
EPS Next 5 Year
40.69%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
253.14%
Revenue Next 5 Year
138.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PROVENTION BIO INC / PRVB Forecast FAQ
When does PROVENTION BIO INC (PRVB) report earnings?
PROVENTION BIO INC (PRVB) will report earnings on 2023-08-02, before the market open.
What are the consensus estimates for PROVENTION BIO INC (PRVB) next earnings?
The consensus EPS estimate for the next earnings of PROVENTION BIO INC (PRVB) is -0.88 USD and the consensus revenue estimate is 3.57M USD.
How do analysts rate PROVENTION BIO INC (PRVB)?
The consensus rating for PROVENTION BIO INC (PRVB) is 78.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.